NEXUS SURGICAL AND MEDICARE LI is a Finance company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2 | 2 | 3 | 6 | 8 |
| EBITDA (ex other income) | 0 | 0 | 0 | 1 | 1 |
| margin % | 15.4 | 13.9 | 7.7 | 11.6 | 12.2 |
| Owners' profit | 0 | 0 | 0 | 0 | 1 |
| EPS, as reported (₹) | 0.53 | 0.31 | 0.39 | 0.91 | 1.35 |
| ROE % · ROCE % | 159.3 · 213.0 | 48.4 · 64.8 | 37.7 · 51.3 | 46.8 · 62.8 | 40.9 · 54.9 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (0) | 1 | (0) | 0 | 0 |
| Capex | (0) | (0) | (0) | (0) | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 1 | 1 | 1 | 2 | 1 | 3 | 2 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.16 | 0.38 | 0.21 | 0.16 | 0.28 | 0.32 | 0.31 | 0.44 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| CRISIL LTD | 34,342 | 38.9 | 10.50 | — | 13.7 | 16.1 | — | 30.6 |
| ONEMI TECHNOLOGY SOL LTD | 5,526 | 19.6 | 4.12 | 9.4 | 21.0 | 18.8 | — | 32.0 |
| GYFTR LIMITED | 1,359 | — | 2.80 | 41.8 | 4.5 | 5.3 | 32.8 | 4.3 |
| CENTRUM CAPITAL LIMITED | 1,077 | — | 0.82 | 9.7 | (21.4) | (2.5) | 49.7 | 29.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · BSE price movement query: company says move is market-driven | regulatory legal | medium | — | — |
| 3 Sept 2026 · Nexus Surgical FY26 Annual Report and 35th AGM Notice | compliance | low | — | — |
| 3 Sept 2026 · Nexus Surgical Medicare 35th AGM notice for 25 Sep 2026 via video conferencing | board shareholder meetings | low | — | — |
| 2 Sept 2026 · 35th AGM scheduled for 25 September 2026 via video conferencing | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Board reconstitutes Audit, Nomination and Stakeholders committees | management changes | medium | — | — |
| 2 Sept 2026 · Re-appointment of Independent Director for second 5-year term | management changes | medium | — | — |
| 2 Sept 2026 · New Independent Director appointed for 5-year term | management changes | medium | — | — |
| 2 Sept 2026 · Nexus Surgical appoints Anish More as Additional Director, proposes him as MD | management changes | high | — | — |
| 2 Sept 2026 · Managing Director resigns, stays on Board as Non-Executive Director | management changes | critical | — | — |
| 2 Sept 2026 · BSE seeks clarification from Nexus Surgical on price movement | regulatory legal | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| PRIME SECURITIES LIMITED |
| 961 |
| 171.5 |
| 3.75 |
| 87.4 |
| 5.1 |
| — |
| 25.7 |
| 19.0 |
| WEALTH FRST PORT. MG. LTD | 900 | 27.3 | 5.29 | 17.3 | 22.5 | 30.3 | — | 97.5 |
| STELLANT SECURITIES (INDIA) LT | 559 | — | 1784.58 | — | 18.2 | 18.2 | — | 56.7 |
| THE INVEST TRUST OF IND L | 511 | 15.3 | 0.70 | 7.1 | 4.7 | 3.9 | (2.4) | 23.4 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 24.8 | 17.9 | 59 of 95 | 38% |
| P/B | 10.2 | 1.2 | 95 of 101 | 6% |
| ROCE | 54.9 | 1.6 | 2 of 84 | 99% |
| ROE | 40.9 | 1.3 | 2 of 115 | 99% |
| Debt / Equity | 0.0 | 0.0 | 4 of 115 | 37% |
| EBITDA margin | 15.6 | 25.6 | 52 of 91 | 43% |
| Revenue growth | 38.1 | (4.1) | 26 of 85 | 70% |
| Profit growth | 171.7 | (0.2) | 14 of 109 | 88% |
| Market cap | 18 | 28 | 69 of 109 | 37% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
